Stock of Ikena Oncology Downgraded by Wedbush after Lead Program Termination
Wednesday, 29 May 2024, 05:08
Wedbush downgrades Ikena Oncology stock, cites lead program discontinuation
In a recent development, Wedbush has downgraded the stock of Ikena Oncology citing the discontinuation of its lead program as the reason for the downgrade. This decision highlights the concerns surrounding the company's future prospects.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.